Missing gut bacterium calms colitis in mice, and it’s low in humans too

If you have ulcerative colitis (UC), or you suspect your digestive troubles trace back to your gut bacteria, you have probably wondered why some people's guts seem to tip into chronic inflammation while others stay calm. A new study offers one concrete answer: a specific species of a common gut bacterium is markedly scarcer in people with UC, and in mice, a strain of that same species triggers a chain of molecular events that shuts down inflammation and repairs the damaged gut lining. The mouse mechanism is detailed and rigorously tested; the human side of the story, so far, only shows a correlation.

Key takeaways

• The bacterial species Blautia wexlerae is present at under a third the level in the intestines of people with ulcerative colitis compared to healthy people, and giving mice a specific lab-isolated strain of it, called HGD16, calmed colitis by way of a metabolite and an immune receptor.
• The mechanism, confirmed with genetically engineered mice, runs through a molecule called indole-3-butyric acid (IBA) acting on immune cells via a receptor called GPR40, and separately through boosting another gut microbe that produces the gut-protective compound butyrate.
• The human portion of the study is a correlational cohort of 32 UC patients and 32 healthy volunteers, not a clinical trial: no person in this study was given the bacterium, so there is no human evidence yet that it treats UC.
• This is not an approved or tested probiotic; nothing here supports buying a Blautia supplement to self-treat UC.

Blautia wexlerae Depletion Found in Ulcerative Colitis Patients

Researchers found that the bacterial species Blautia wexlerae (a member of gut bacteria in the Lachnospiraceae family) was markedly less abundant in the intestines of people with ulcerative colitis than in healthy people, and that giving mice one particular lab-grown strain of it, labeled HGD16, calmed colitis symptoms and repaired gut tissue damage. The study, published in Cell Reports by researchers at Hubei University of Technology and Wuhan University, describes two mechanisms: one metabolite calming the immune system, and a second knock-on effect that boosts a different gut bacterium known for producing a gut-protective molecule called butyrate.

Why Ulcerative Colitis Patients Should Pay Attention

Ulcerative colitis is a form of inflammatory bowel disease (IBD) that causes chronic inflammation and ulcers in the lining of the colon, and current drug options come with real trade-offs. Standard treatments, from anti-inflammatory drugs to steroids to biologic medications and immunosuppressants, can quickly control flares but carry risks of drug resistance and organ damage with long-term use, while fecal microbiota transplants (introducing a healthy person's gut bacteria into a patient) remain experimental and unproven for safety. That gap is exactly why researchers keep hunting for specific bacteria and their byproducts that calm gut inflammation without the same side-effect profile, and this study adds Blautia wexlerae and its metabolite to that short list of candidates worth investigating further.

Study Design Combined a Human Cohort With a Mouse Colitis Model

The researchers first recruited 85 volunteers at a hospital in China, and after excluding people who didn't meet criteria or complete testing, ended up comparing stool, blood, and colon tissue from 32 healthy volunteers against 32 people with active mild to moderate UC. In that comparison, butyric acid (a short-chain fatty acid, a small molecule gut bacteria make by fermenting fiber) was lower in UC patients' feces, and Blautia was one of several bacterial genera reduced in their gut microbiota, correlating with worse disease scores. From there, the team isolated three Blautia strains from healthy people's stool and tested each one in mice with chemically induced colitis (using a compound called DSS that damages the colon lining to mimic the disease). Only the HGD16 strain of B. wexlerae reduced disease severity; the other two strains, B. faecis and B. obeum, did nothing. The team then ran a series of additional mouse experiments, including drugs that block specific pathways and custom-bred mice missing a single immune receptor, to trace exactly how HGD16 works.

What This Means if You're Managing UC

Nothing in this study is a ready-to-use treatment. No human volunteer in the cohort was actually given B. wexlerae or its metabolite; the human data only shows that people with lower levels of this bacterial species, and lower levels of its associated metabolite and receptor, tend to have more severe UC. The mouse work is what shows the HGD16 strain can actively calm inflammation, not just correlate with its absence. If you're researching gut-based approaches to UC, this is a reasonable study to bring up with a gastroenterologist as an example of active research, but it does not support buying a Blautia supplement, high-dose butyrate, or any commercial probiotic marketed for colitis relief, since none of those products were tested here and the human clinical trial referenced by the researchers as a next step has not yet happened. The finding is best read as an early signal pointing toward possible future biomarkers and therapies, not a validated intervention today.

Key Limitations: Human Data Is Correlational, Not a Treatment Trial

The most important caveat is one the researchers themselves acknowledge: the human arm of this study is a correlational cohort, comparing existing bacteria and metabolite levels between two groups of 32 people, not an interventional trial that gave anyone the bacterium and watched for improvement. All of the mechanism proving HGD16 actually treats colitis (the metabolite pathway, the immune receptor, the knockout mice) comes from mice, and the authors note several additional limits, including that every mouse used was male, so sex-specific effects are unknown, and the precise interaction between B. wexlerae and the second beneficial bacterium it boosts (Faecalibacterium butyricigenerans) hasn't been fully worked out; the authors describe it as a hypothesized mutual relationship still needing confirmation.

What Comes Next for This Colitis Research

The study authors state plainly that these findings are meant to inform future clinical trials of B. wexlerae itself, since a strain shown to work in a mouse model of colitis is not automatically safe or effective in people. The paper also points toward two other directions worth watching: using levels of the metabolite IBA, the species B. wexlerae, and the receptor GPR40 together as a potential early screening signal for UC risk, and exploring whether boosting butyrate-producing bacteria like Faecalibacterium butyricigenerans could improve existing fecal microbiota transplant therapies. No timeline was given for when a human trial of the bacterium itself might begin.

Common Questions

Is Blautia wexlerae a proven treatment for ulcerative colitis I can take now? No. The HGD16 strain has only been tested in mice with chemically induced colitis; no human has been given this bacterium in a clinical trial, so there's no evidence yet that supplementing with it is safe or effective for people with UC.

What is indole-3-butyric acid (IBA) and why does it matter here? IBA is a small molecule that the bacterial strain HGD16 produces, and in mice it calmed colitis by acting on a receptor called GPR40 on immune cells called macrophages, which in turn shut down an inflammatory signaling pathway and helped repair the gut lining.

Does this mean eating more fiber or taking probiotics helps ulcerative colitis? The study didn't test fiber intake or commercial probiotics in humans, so it can't confirm that. What it does show, in mice, is that a specific bacterial strain and the gut-protective compound butyrate that a related bacterium produces both eased colitis, which supports the broader, already well-documented idea that short-chain fatty acids like butyrate matter for gut healing, without proving any specific diet change or supplement works for UC.

How did researchers find this particular bacterial strain? They compared gut bacteria between 32 healthy volunteers and 32 UC patients, noticed the species Blautia wexlerae was depleted in the UC group, then isolated three different Blautia strains from healthy people's stool and tested each one directly in colitis mice; only one of the three, B. wexlerae HGD16, worked.

References

Yang Chen, Binbin Long, Mengyuan Liu, et al. (2026). Blautia wexlerae ameliorates ulcerative colitis via metabolic remodeling of the gut microbiota. Cell Reports. https://doi.org/10.1016/j.celrep.2026.117977